Abstract
Background The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown.
Method We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: https:ClinicalTrials.gov NCT04411576).
Results Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)).
Conclusion Presence of viral antibodies marks past disease and protection against excess risk of future disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04411576
Funding Statement
This work was supported by the Karolinska University Hospital (KUH); the County Council of Stockholm; Erling-Persson family foundation; KTH Royal Institute of Technology; Creades and SciLifeLab. Role of funder was as employer of the study team, providing facilities and resources (KUH, KTH and SciLifeLab) and also assisted with enrolment (KUH). There were no other roles for the funders in design or execution of the study, in analysis and interpretation of data or in the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the National Ethical Review Agency of Sweden (Decision number 2020-01620).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: None of the authors have any conflicts of interest to declare.
Funding:This work was supported by the Karolinska University Hospital (KUH); the County Council of Stockholm; Erling-Persson family foundation; KTH Royal Institute of Technology; Creades and SciLifeLab. Role of funder was as employer of the study team, providing facilities and resources (KUH, KTH and SciLifeLab) and also assisted with enrolment (KUH). There were no other roles for the funders in design or execution of the study, in analysis and interpretation of data or in the decision to submit for publication.
Data Availability
The data constitutes sensitive data about health of human research subjects. However, pseudonymised, individual-level data that allow full replication of the results in this article are freely available from joakim.dillner{at}sll.se or from the Karolinska University Hospital data analysis department: tableau.karolinska{at}sll.se
